Logo Logo

Research Studies Closed to Enrollment and in Analysis

Research Studies Closed to Enrollment and/or in Analysis

  • Sponsor: Ola HAWAII, National Institute of Minority Health and Health Disparities (NIMHD)
  • Principal Investigators: Gehan Devendra MD and Juwon Park PhD
  • Project Summary:This study aims to study the role of monocytes in the development and persistence of pulmonary Post-Acute Sequelae of SARS-CoV-2 infection (Pulmonary Long COVID) and how macro-social and psychological determinants may influence these biological mechanisms.

  • Sponsor: National Institute of Health
  • Hawaiʻi Site Principal Investigator: Cecilia M. Shikuma MD
  • Project Summary:This national initiative is dedicated to understanding, diagnosing, preventing and treating Long COVID. The Hawaiʻi site recruited 110 participants into this national study.

  • Sponsor: National Institute of Health
  • Hawaiʻi Site Principal Investigator: Cecilia M. Shikuma MD
  • Project Summary: A prospective, multi-center, multi-arm, randomized controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms. Hawaiʻi participated in the evaluation of Appendix B Ivabradine and Coordinated Care study, recruiting 11 participants into the study.

  • Sponsor: Gilead Sciences, Merck Sharp & Dohme
  • Hawaiʻi Site Principal Investigator: Cecilia M. Shikuma MD
  • Project Summary: The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologically suppressed people with HIV (PWH) at Week 24. 

  • Sponsor: IDeA States Consortium for Clinical Research (ISCORE), University of Mississippi, National Institute of General Medical Sciences (NIGMS)
  • Hawaiʻi Site Principal Investigator: Cecilia M. Shikuma MD
  • Project Summary: The purpose of this study is to learn the effects of Immulina™, a natural dietary supplement derived from a microbe called Spirulina, on specific immune substances (called biomarkers) in the blood that are associated with improving the ability to “bounce back” against long-term symptoms caused by a COVID-19 infection.

  • Sponsor: Myra W. and Jean Kent Angus Foundation
  • Principal Investigator: Cecilia M. Shikuma MD
  • Project Summary: The goal of this project was to understand the immune-biologic basis of COVID-19 infection among the diverse racial and ethnic population of Hawaiʻi

  • Sponsor: Hawaiʻi Community Foundation
  • Principal Investigator: Cecilia M. Shikuma MD
  • Project Summary: The project will examine the hypothesis that pulmonary PASC develops as a consequence of AA mediated binding of ACE2

  • Sponsor: MannKind Corporation
  • Hawaiʻi Site Principal Investigator: Erlaine Bello MD
  • Project Summary: Nontuberculous mycobacterial (NTM) lung disease is a chronic lung infection caused by bacteria commonly found in the environment, specifically in soil and water. While most people are exposed to NTM without developing illness, certain individuals with underlying lung conditions or weakened immune systems are at higher risk. Hawaiʻi has the highest rate of NTM lung disease in the United States. This clinical trial will compare the efficacy and safety of inhalational Clofazimine vs placebo when added to guideline-based therapy (GBT) for this disease. Inhalational clofazimine has the benefit of not causing skin discoloration typical of oral clofazimine.